Trends in antimicrobial drug development: Implications for the future

Clinical Infectious Diseases

Volumn 38, Issue 9, 2004, Pages 1279-1286

  Spellberg, Brad ^a   Powers, John H ^c   Brass, Eric P ^a,b   Miller, Loren G ^a,b   Edwards Jr , John E ^a,b,d  

^a Los Angeles Biomedical Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFDITOREN PIVOXIL; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; GATIFLOXACIN; GEMIFLOXACIN; LINEZOLID; MOXIFLOXACIN; RIFAPENTINE;

ARTICLE; BIOTECHNOLOGY; DATA BASE; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; DRUG APPROVAL; DRUG DESIGN; FORECASTING; HUMAN; MULTIDRUG RESISTANCE; PHARMACEUTICS; STATISTICS; SYNTHESIS; UNITED STATES;

ANTI-BACTERIAL AGENTS; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FORECASTING; HUMANS; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 2342595765     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/420937     Document Type: Article

References (79)

1. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996; 275:189-93.
2. World Health Organization (WHO). Deaths by cause, sex and mortality stratum in WHO Regions, estimates for 2001. World Health Report - 2002. Geneva: WHO, 2002.
3. Wenzel RP, Edmond MB. Managing antibiotic resistance. N Engl J Med 2000; 343:1961-3.
4. Gilligan PH. Therapeutic challenges posed by bacterial bioterrorism threats. Curr Opin Microbiol 2002; 5:489-95.
5. Smolinski MS, Hamburg MA, Lederberg J, eds. Microbial threats to health: emergence, detection, and response. Washington, DC: Institute of Medicine, 2003.
6. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815-26.
7. Gilbert DN, Edwards JE Jr. Is there hope for the prevention of future antimicrobial shortages? Clin Infect Dis 2002; 35:215-6 [author reply appears on 6-7].
8. Shlaes DM, Moellering RC Jr. The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis 2002; 34:420-2.
9. DiMassa JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151-85.
10. Projan SJ. Why is Big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6:427-30.
11. Powers JH. Development of drugs for antimicrobial-resistant pathogens. Curr Opin Infect Dis 2003; 16:547-51.
12. FDA new molecular entities (NMEs) reports. Bethesda, MD: US Food and Drug Administration. Available at: http://www.fda.gov/cder/rdmt/default.htm. Accessed on 29 April 2003.
13. FDA drug approvals list. Bethesda, MD: US Food and Drug Administration. Available at: http://www.fda.gov/cder/da/da.htm. Accessed 24 January 2003.
14. Merck annual report 2002 - research pipeline review. Whitehouse Station, NJ: Merck. Available at: http://www.merck.com/finance/annual-report/ar2002/ research_pipeline.html. Accessed on 24 March 2003.
15. Merck annual report 1998. Whitehouse Station, NJ: Merck. Available at: http://www.merck.com/overview/98ar/p3.htm. Accessed on 30 March 2003.
16. Johnson & Johnson Innovations. Pharmaceutical pipeline. New Brunswick, NJ: Johnson & Johnson. Available at: http://www.jnj.com/ innovations/pharma_pipeline/index.htm. Accessed on 26 March 2003.
17. Johnson & Johnson Innovations. 2002 Annual report. Johnson & Johnson. New Brunswick, NJ: Johnson & Johnson. Available at: http://www.jnj.com/2002AnnualReport/index.htm. Accessed on 26 March 2003.
18. Johnson & Johnson Innovations. 1999 Annual report. New Brunswick, NJ: Johnson & Johnson. Available at: http://www.investor.jnj.com/downloads/ 1999ar.pdf. Accessed on 30 March 2003.
19. Pfizer. Annual report 2002. New London, CT: Pfizer. Available at: http://www.pfizer.com/are/investors_reports/annual_2002/pfizer2002.pdf. Accessed 24 March 2003.
20. Pfizer. Financial summary (1997-2003). New London, CT: Pfizer. Available at: http://www.pfizer.com/are/investors_reports/annual_2002/p2002ar69.htm. Accessed on 30 March 2003.
21. GlaxoSmithKline. Product pipeline overview. London: GlaxoSmithKline. Available at: http://science.gsk.com/pipeline/index.htm. Accessed on 24 March 2003.
22. Bristol-Myers Squibb Pharmaceutical Research Institute. Development compounds, 2002. New York: Bristol-Myers Squibb. Available at: http://www.bms.com/research/data/dvcomp.html. Accessed on 24 March 2003.
23. Bristol-Myers Squibb Pharmaceutical Research Institute. Press release: full year results. New York: Bristol-Myers Squibb. Available at: http://www.bms.com/news/press/data/fg_press_release_3440.html. Accessed on 30 March 2003.
24. Bristol-Myers Squibb Pharmaceutical Research Institute. 1998 Annual report. New York: Bristol-Myers Squibb.
25. Aventis SA. Aventis pipeline. Strasbourg, France: Aventis. Available at: http://www.aventis.com/main/page.asp?pageid=51447882431671521836. Accessed on 25 March 2003.
26. Pharmacia. Pharmacia pipeline products. Peapack, NJ: Pharmacia. Available at: http://www.pharmacia.com/investor/pipeline.asp. Accessed on 28 March 2003.
27. Novartis AG. Novartis annual report 2002: compounds in development. Basel, Switzerland: Norvartis. Available at: http://www.novartis.com/ annual_reports/2002/en/download/pharma_dvp.pdf. Accessed on 24 March 2003.
28. F. Hoffmann-La Roche. Roche product pipeline. Basel, Switzerland: F. Hoffman La Roche. Available at: http://www.roche.com/science-pipeline-detail?ta= Choose+an+area=Choose+a+phase=Show+ pipeline. Accessed on 26 March 2003.
29. F. Hoffmann-La Roche. 2002 Annual report key figures. Basel, Switzerland: F. Hoffman La Roche. Available at: http://www.roche.com/pages/downloads/ investor/pdf/reports/gb02/e01.pdf. Accessed on 30 March 2003.
30. F. Hoffmann-La Roche. 1999 Annual report key figures. Basel, Switzerland: F. Hoffman La Roche. Available at: http://www.roche.com/pages/downloads/ investor/pdf/reports/gb99/e01.pdf. Accessed on 30 March 2003.
31. AstraZeneca annual report 2002. London: AstraZeneca. Available at: http://www.astrazeneca.com/article/11161.aspx. Accessed 25 March 2003.
32. AstraZeneca. 1999 Downloads. London: AstraZeneca. Available at: http://www.astrazeneca.com/article/11161.aspx. Accessed on 30 March 2003.
33. Abbott Laboratories. Abbott Laboratories 2002 annual report and 1998 annual report. Chicago: Abbott Laboratories. Available at: http://abbott.com/ investor/annual_reports.html. Accessed on 30 March 2003.
34. Wyeth. Wyeth product pipeline. Collegeville, PA: Wyeth. Available at: http://www.wyeth.com/research/pipeline.asp. Accessed on 26 March 2003.
35. Wyeth. Annual reports. Collegeville, PA: Wyeth. Available at: http://investor.wyeth.com/ireye/ir_site.zhtml?ticker=WYE=700. Accessed on 30 March 2003.
36. Eli Lilly and Co. Lilly 2002 annual report - compounds in late-stage development. Indianapolis, IN: Lilly. Available at: http://www.lilly.com/ investor/annual_report/lillyar2002complete.pdf. Accessed on 26 March 2003.
37. Eli Lilly and Co. 2002 Annual report. Indianapolis, IN: Lilly. Available at: http://www.lilly.com/investor/annual_report/lillyar2002complete.pdf. Accessed on 26 March 2003.
38. Eli Lilly and Co. 2000 Annual report. Indianapolis, IN: Lilly. Available at: http://www.lilly.com/investor/annual_report/lillyar2000editorial.pdf. Accessed on 26 March 2003.
39. Schering-Plough and Co. Schering-Plough product pipeline. Kenilworth, NJ: Schering-Plough and Co. Available at: http://www.schering-plough.com/pdf/ PP_0204_1page.pdf. Accessed in February 2004.
40. Schering-Plough and Co. 2002 And 1999 annual reports. Kenilworth, NJ: Schering-Plough and Co. Available at: http://phx.corporate-ir.net/phoenix.zhtml? c=89839&p=irol-reports. Accessed on 30 March 2003.
41. Bayer AG. Bayer 2002 annual report. Leverkusen, Germany: Bayer. Available at: http://www.investor.bayer.com/1572_2001/2001.php#reports. Accessed on 28 March 2003.
42. The 2002 Fortune 500. Fortune Magazine. Available at: http://www.fortune.com/fortune/fortune500/0,14924,101,00.html. Accessed on 28 March 2003.
43. The 2002 global 500. Fortune Magazine. 15 April 2002.
44. The 2002 global 500. 15 April 2002.
45. Biotechnology industry profile: top biotechnology companies by sales. Yahoo! Finance. Available at: http://biz.yahoo.com/ic/9.html. Accessed on 16 April 2003.
46. Amgen. Amgen product pipeline. Thousand Oaks, CA: Amgen. Available at: http://www.amgen.com/product/pipeline.html. Accessed on 16 April 2003.
47. Genentech. Genentech product pipeline. South San Francisco, CA: Genentech. Available at: http://www.genentech.com/gene/pipeline/status/. Accessed on 16 April 2003.
48. Applera. Applera annual report 2002. Norwalk, CT: Applera. Available at: http://www.applera.com/invest/ar2002.html. Accessed 16 April 2003.
49. Genzyme. Genzyme product pipeline. Cambridge, MA: Genzyme. Available at: http://www.genzyme.com/research/pipeline/pipe_home.asp. Accessed on 16 April 2003.
50. Serono. Serono Group product pipeline. Geneva, Switzerland: Serono Group. Available at: http://www.serono.com/pipeline/pipeline.jsp?major=2. Accessed on 16 April 2003.
51. Chiron. Chiron product pipeline. Emeryville, CA: Chiron. Available at: http://www.chiron.com/pipeline/biopharmapipe/index.html. Accessed on 16 April 2003.
52. Biogen. Cambridge, MA: Biogen. Biogen product pipeline. Available at: http://www.biogen.com/site/025.html. Accessed 16 April 2003.
53. Burrill GS. Biotech 2003. San Francisco: Burrill & Company, 2003.
54. Cubist Pharmaceutical. Product development. Lexington, MA: Cubist Pharmaceutical. Available at: http://www.cubist.com/product_devt/. Accessed on 15 September 2003.
55. InterMune. Oritavancin. Brisbane, CA: InterMune. Available at: http://www.intermune.com/wt/itmn/oritavancin. Accessed on 15 September 2003.
56. Vicuron Pharmaceuticals. Vicuron pipeline. King of Prussia, PA: Vicuron. Available at: http://www.vicuron.com/products/pipeline.html. Accessed on 15 September 2003.
57. Debono M, Abbott BJ, Molloy RM, et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J Antibiot (Tokyo) 1988; 41:1093-105.
58. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36:131-9.
59. Public health officials investigating staph infections among LA County jail inmates. Los Angeles: Los Angeles County Department of Health Services, 2003. Available at: http://www.lapublichealth.org/acd/docs/mrsaoutbrkfinal.pdf. Accessed on 27 March 2003.
60. LaMar JE, Carr RB, Zinderman C, McDonald K. Sentinel cases of community-acquired methicillin-resistant Staphylococcus aureus onboard a naval ship. Mil Med 2003; 168:135-8.
61. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-24.
62. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857-62.
63. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2001; 50:800-4.
64. Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2003; 46:285-9.
65. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
66. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.
67. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.
68. Auckland C, Teare L, Cooke F, et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002; 50:743-6.
69. Johnson AP, Tysall L, Stockdale MV, et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002; 21:751-4.
70. Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol 1996; 44:317-9.
71. Douglas MW, Mulholland K, Denyer V, Gottlieb T. Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unit - an infection control study. Burns 2001; 27:131-5.
72. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-11.
73. Muller M, McGeer A, Willey BM, et al. Outbreaks of multi-drug resistant Escherichia coli in long-term care facilities in the Durham, York and Toronto regions of Ontario, 2000-2002. Can Commun Dis Rep 2002; 28:113-8.
74. Zansky S, Wallace B, Schoonmaker-Bopp D, et al. From the Centers for Disease Control and Prevention: outbreak of multi-drug resistant Salmonella Newport - United States, January-April 2002. JAMA 2002; 288:951-3.
75. Nachega JB, Chaisson RE. Tuberculosis drug resistance: a global threat. Clin Infect Dis 2003; 36(Suppl 1):S24-30.
76. Grant GR, Lederman JA, Brandstetter RD. T.G. Heaton, tuberculosis, and artificial pneumothorax: once again, back to the future? Chest 1997; 112:7-8.
77. Kir A, Tahaoglu K, Okur E, Hatipoglu T. Role of surgery in multi-drug-resistant tuberculosis: results of 27 cases. Eur J Cardiothorac Surg 1997; 12:531-4.
78. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000.
79. Senator Feinstein introduces national battle plan against cancer. Available at: http://feinstein.senate.gov/03Releases/r-cancer03.htm. Accessed on 6 June 2003.